TITLE:
hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance
AUTHORS:
Suzan Wadi, Aaron R. Tipton, Jill A. Trendel, Sadik A. Khuder, Deborah J. Vestal
KEYWORDS:
Guanylate-Binding Protein, Paclitaxel, Ovarian Cancer, Drug Resistance, GTPase, TUBB3
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.13,
December
8,
2016
ABSTRACT: Ovarian
cancer is the gynecological cancer with the poorest prognosis. One significant
reason is the development of resistance to the chemotherapeutic drugs used in
its treatment. The large GTPase, hGBP-1, has been implicated in paclitaxel
resistance in ovarian cell lines. Forced expression of hGBP-1 in SKOV3 ovarian
cancer cells protects them from paclitaxel-induced cell death. However, prior
to this study, nothing was known about whether hGBP-1 was expressed in ovarian
tumors and whether its expression correlated with paclitaxel resistance. hGBP-1
is expressed in 17% of ovarian tumors from patients that have not yet received
treatment. However, at least 80% of the ovarian tumors that recurred after
therapies that included a taxane, either paclitaxel or docetaxel, were positive
for hGBP-1. In addition, hGBP-1 expression predicts a significantly shorter
progression-free survival in ovarian cancers. Based on these studies, hGBP-1
could prove to be a potential biomarker for paclitaxel resistance in ovarian
cancer.